Navigation Links
Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
Date:5/27/2008

KENILWORTH, N.J., May 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that Janet M. Barth has been appointed vice president, investor relations, effective immediately.

In this role, Barth will be responsible for developing, implementing and continually improving a comprehensive global investor relations program for Schering-Plough. She will lead the formulation and execution of external and internal investor communications plans to support Schering-Plough's business objectives. She also will partner with the company's senior management team on matters pertaining to the investment community and individual shareholders.

Barth reports to Alex Kelly, group vice president, global communications and investor relations. She assumes the investor relations responsibilities that were previously fulfilled by Kelly, who was named to his current expanded role in October 2007.

Barth most recently served as senior vice president, investor relations and corporate communications, for Adams Respiratory Therapeutics, which was a newly public specialty pharmaceutical company. In that role, she established, developed and directed comprehensive investor relations and corporate communications programs for the company prior to its acquisition by Reckitt Benckiser in January 2008.

Previously, Barth was employed for 14 years by Schering-Plough, where she held various positions of increasing responsibility, including that of director, investor relations. Barth holds a Bachelor of Arts degree in policy and management studies from Dickinson College, Carlisle, Pa., and a Master of Business Administration degree from Seton Hall University, South Orange, N.J. She joined the National Investor Relations Institute (NIRI) in 1996 and currently is a member of NIRI's New York and Virtual Chapters. Barth completed a 12-month leadership development program with Women Unlimited LEAD (Leadership Education and Development) in 2005.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... One Million Solutions ... (SafeTEC™), $3 million in investment towards 15+ TEC Validation Projects™. As a pre-competitive ... their applicability in drug safety assessment, for the industry as a whole. , ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/16/2017)... , Jan. 16, 2017  Eurofins Genomics today ... will allow more customers to receive their primers in ... or compromise in quality found with other providers. Express ... United States at no additional fee. ... routine genetic studies, including DNA sequencing, genotyping, site-directed mutagenesis, ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global ... ... CAGR of 16.83% during the period 2017-2021. The report ... market for 2017-2021. To calculate the market size, the report considers the ... also includes a a discussion of the key vendors operating in this ...
Breaking Biology Technology:
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
(Date:1/3/2017)... Onitor, provider of digital health technology for ... innovative biometric data-driven program designed to aid weight loss ... 2017 Consumer Electronics Show (CES) in Las ... the World Health Organization (WHO), have identified lifestyle risks ... are overweight or obese. WHO also states that more ...
Breaking Biology News(10 mins):